InnoStrat serves the clinical, medical and commercial functions of Life Science companies, identifying innovative business opportunities, developing competitive strategies, and ensuring world-class implementation through behavioural science, digital innovations and managing change.

K/S Manor Road was a real-estate investment company that managed a London property where Virgin Active was the tenant. As chairman of the board I drove a substantial turn-around, including finding a new tenant, securing new financing and re-negotiating administration agreements. The property was sold in 2023, after which the investment company was voluntarily and solvently liquidated.

Sample Prep Business Unit, Biosciences Division, Life Sciences Solutions Group (LSG). Member of the BU Leadership Team.RESPONSIBILITIES- To own the strategy (strategic plans, execution tactics, budgets, inorganic pipeline reviews) in alignment with the BU’s Vice President and the Division Leadership Team.- To establish and improve BU mechanisms (dashboards, reviews, meetings).- To manage alliances with customers and internal partners.- To support key transformations (culture changes, tech transfers, etc.).SUCCESSES- Created the first Strategy Playbook and 5-year strategic plan for this new business unit, including portfolio optimization plans, headcount and BD focus areas.- Drove a culture change in the leadership team to ensure effective collaboration across multiple sites by using dashboards, accountability maps, and other mechanisms.- Successfully represented the customer interests in major projects to a) expand the manufacturing capacity of a regulated product portfolio, and b) transfer the manufacturing site of an essential instrument portfolio.

Licensing and Commercial Supply, Life Sciences Solutions Group (LSG).RESPONSIBILITIES- To develop a strategy for doubling the Dynabeads® beads business from 2018 to 2024.- To manage strategic alliances with the largest customers with the aim to develop and supply OEM products for diagnostic and pharmaceutical use. - To transfer core manufacturing technology to a key customer.- To serve as interim manager for the group’s R&D and Marketing functions in Molecular Diagnostics from August 2014 to April 2015.- From January 2016: Promoted to Director and member of the Site Norway Leadership Team with additional responsibilities for Site Norway program management and culture changes.SUCCESSES- Completed all tech transfer projects on time and within budget.- Part of the team that negotiated and executed an OEM agreement with Novartis for supply of critical components to its cell-therapy drug Kymriah (tisagenlecleucel).- Helped negotiate OEM agreements with global IVD companies for Thermo Fisher’s immunodiagnostics and molecular diagnostics products.- Consistently exceeded all revenue and EBITA targets.- The site earned prestigious awards for product innovation in 2017-2018: The Norwegian Industrial Board's "Norway's Smartest Company Award" (2018), The Norwegian Research Council's "Innovation Award" (2017) and the Norwegian Engineering Industry's "Tech Award" (2017).

RESPONSIBILITIES- Manager of nine employees- Oversee the timely and accurate delivery of competitive intelligence to Executive Management, R&D teams and other internal stakeholders.SUCCESSES- Delivered strategic competitive intelligence on a timely basis to key stakeholders including the Board of Directors and Executive Management.- Met all KPIs and timelines for input to development projects and strategy review processes.

RESPONSIBILITIES- Manager of up to 10 employees.- To develop and execute key Global Medical Affairs projects at the pre-launch and peri-launch stages, typically medical education programmes aiming to ensure science-based advocacy among key external stakeholders at launch.SUCCESSES2011: Achieved 100% unaided awareness of Tresiba® (insulin degludec) among global KOLs two years before launch. Implemented global publication-planning process.2010: Exceeded the global enrolment targets for the SOLVE observational study of Levemir® (insulin detemir) in all 11 countries.2009: Planned and executed scientific expert meetings for 110 KOLs to explore the science of Victoza® (liraglutide). Launched the global diabetes expert directory (“DxD”) to improve business processes and regulatory compliance regarding Health Care Professional interactions.2008: Established a new project-management department, hired seven employees, and ensured strategic alignment with the top eight affiliates.

RESPONSIBILITIES- To conduct an observational study of insulin detemir in 50,000+ diabetes patients, involving 8,000+ physicians in more than 25 countries.- From February 2007: Promoted to Principal Scientist with additional responsibility for department process improvements.SUCCESSES:- Achieved all global targets for the study, delivering extensive scientific support for the brand.- Planned and conducted global results meeting for ~300 physicians and diabetes nurses.- Met all project KPIs for my countries (UK, Ireland, USA, Canada, Spain, France).

Self-employed Management Consultant supporting life-science companies in UK, Germany and Denmark with strategic analyses, sales-force effectiveness, marketing and general management.

Development and global marketing of analytical instruments for biotech research. I established the sales and marketing department, Vir’s corporate identity and sales & marketing systems and processes. Manager of 3 employees.

IT services for the European life science industry. I defined the company’s strategy with the CEO, and I surpassed the sales targets as lead consultant and project manager. I was also a key player in securing venture capital funding in November 2000. Manager of 3 employees.

Managed the marketing parts of a global strategic alliance with Roche Pharma for Herceptest, DAKO's companion diagnostic for Herceptin (trastuzumab). Negotiated the acquisition of a minor German competitor.

Global product management of immunohistochemical systems and reagents

Export sales via distributors in Europe

I held positions as Product Specialist (Denmark), Senior Investigator (UK), Customer Support Specialist (France) and Marketing Planner (France). During my tenure, the company changed ownership and name several times: Amersham Int'l, Kodak Clinical Diagnostics, ADL, Johnson&Johnson.